>>GOOD MORNING AND WELCOME TO THE FIRST MEETING OF THE HUMAN FETAL TISSUE RESEARCH ETHICS ADVISORY BOARD FOR FISCAL YEAR 2020. SO TODAY'S MEETING, THE MORNING PORTION IS OPEN TO THE APPROXIMATE UBIQUITINNATION LICK AND BROADCAST ON THE NIH VIDEOCAST NETWORK. A CLOSED SESSION WILL FOLLOW. WHERE DISCUSSION OF SPECIFIC RESEARCH PROPOSALS WILL TAKE PLACE. WE REALLY APPRECIATE THE WILLINGNESS OF ALL OF THE MEMBERS WHO HAVE AGREED TO SERVE ON THIS BOARD. I WANT TO THANK YOU FOR THE WORK THAT YOU'VE ALREADY DONE AND FOR MAKING TIME AND REARRANGING YOUR SCHEDULES TO JOIN THE MEETING TODAY. I ALSO WANT TO THANK MEMBERS OF THE PUBLIC WHO HAVE SIGNED UP TO DELIVER PUBLIC COMMENTS DURING THE OPEN SESSION TODAY AND TO THOSE WHO SENT IN COMMENTS AHEAD OF TIME. OF COURSE I HOPE ALL OF YOU AND YOUR FAMILIES ARE IN GOOD HEALTH AS WE ALL CONTINUE TO ENDURE THE UNPRECEDENTED CHALLENGE OF THE COVID-19 PANDEMIC. LET ME TAKE A FEW MOMENTS THAT RECAP THE HISTORY THAT BRINGS US TO THE MEETING TODAY. IN JUNE OF LAST YEAR HHS ANNOUNCED THAT THERE WOULD BE A NEW ETHICS ADVISORY BOARD ESTABLISHED TO REVIEW NEW OR COMPETING RESEARCH PROPOSALS USING HUMAN FETAL TISSUE. HHS ALSO ANNOUNCED THAT NIH INTRAMURAL RESEARCH THAT REQUIRED NEW ACQUISITION FETAL TISSUE FROM ELECTIVE ABORTIONS WOULD NOT BE CONDUCTED. IN FEBRUARY OF THIS YEAR, HHS PUB LIBRARIED A NOTICE ANNOUNCING THE INTENTION TO CONVENE THE EAB FOR FISCAL YEAR 2020 AND SOLICITED NOMINATIONS FOR THE BOARD. SECRETARY CONSIDERED THESE NOMINATIONS AND APPOINTING THE MEMBERS JOINING TODAY. THERE ARE LEGAL REQUIREMENTS SET BY THE PUBLIC HEALTH SERVICES ACT THAT THE BOARD--PHYSICIANS, ETHICISTS, THEOLOGIANS AND ATTORNEYS. THE STATUTE ALSO STATES THAT THE PURPOSE OF THE ETHICS ADVISORY BOARD IS TO ADVISE CONSULT WITH AND MAKE RECOMMENDATIONS TO THE SECRETARY REGARDING THE ETHICS OF RESEARCH PROPOSALS INVOLVING HUMAN FETAL TISSUE. ALL OF THE RESEARCH PROPOSALS THAT ARE BEING CONSIDERED BY THIS BOARD TODAY HAVE ALREADY BEEN RECOMMENDED FOR POTENTIAL FUNDING THROUGH NIH'S 2 LEVEL EXTERNAL SCIENTIFIC REVIEW PROCESS. SO THIS BOARD IS NOT CHARGED WITH CONDUCTING A SCIENTIFIC REVIEW, RATHER RECOMMENDATIONS FROM THIS BOARD WILL ADDRESS WHETHER THE SECRETARY SHOULD OR SHOULD NOT WITHHOLD FUNDS FROM A PROPOSED PROJECT BECAUSE OF ETHICAL CONSIDERATIONS. IN PROVIDING ADVICE AND RECOMMENDATIONS ON THESE MATTERS, THIS BOARD WILL CONSIDER THE USE OF ALTERNATIVES TO THE USE OF HUMAN FETAL TISSUE AND REVIEW AND VERIFY THE CORE ETHICAL PRINCIPLES AND PROCEDURES USED IN THE PROCESS FOR OBTAINING WRITTEN VOLUNTARY INFORMED CONSENT FOR THE DO NATION OF THE TISSUE. ADVICE PROVIDED BY THIS BOARD WILL ADDRESS WHETHER HUMAN FETAL TISSUE IS BEING UTILIZED FOR RESEARCH ONLY WHEN SCIENTIFICALLY JUSTIFIABLE AND IN THE LEAST AMOUNT POSSIBLE TO ACHIEVE THE SCIENTIFIC OUTCOMES. AT THE SAME TIME THAT THE PLAN FOR THE BOARD WAS ANNOUNCED HHS ALSO ANNOUNCED ITS INTENTION TO FUND RESEARCH ON ALTERNATIVE EXPERIMENTAL MODELS THAT DO NOT USE HUMAN FETAL TISSUE. SOME OF THE RESEARCH PROPOSALS TO BE DISCUSSED BY THE BOARD TODAY ARE IN RESPONSE TO THAT EFFORT. AFTER TODAY'S MEETING A REPORT DESCRIBING THE FINDINGS OF THIS BOARD WILL BE SUBMITTED TO THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE SENATE COMMITTEE ON HEALTH EDUCATION LABOR INTENTIONS AND THE HOUSE COMMITTEE ON ENERGY AND COMMERCE. AS REQUIRED BY STATUTE, THE BOARD WILL TERMINATE 30 DAYS AFTER THE DATE ON WHICH THAT REPORT IS SUBMITTED. NOW BEFORE I TURN TO THE BOARD CHAIR, DR. PAIGE CUNNINGHAM ARE THERE ANY QUESTIONS FROM BOARD MEMBERS FOR ME? OKAY, HEARING NONE, I DON'T SEE ANY HANDS RAISED. OKAY. I WILL THANK YOU AGAIN FOR YOUR PARTICIPATION AND WE WILL NOW TURN THE MEETING OVER TO DR. CUNNINGHAM. >> THANK YOU DR. TABAK, WELCOME TO ALL OF YOU. THANK GIVING UP AN ENTIRE FRIDAY PLUS ALL THE TIME YOU SPENT PREPARING AND REVIEWING. FOR SOME OF US IT WAS MORE OF A STRETCH THAN OTHERS IN DIGGING INTO THESE PROPOSALS AND MY SECRETARY TO SECRETARY AZAR AND LEADERSHIP IN AUTHORIZING AND CARRYING FORTH WHAT I BELIEVE TO BE THIS KIND OF INDEPENDENT ETHICS ADVISORY BOARD REVIEWING THESE RULES. OTHERS ARE FAMILIAR WITH THOSE HAPPENING IN THE PAST FEEL FREE TO CORRECT MY UNDERSTANDING OF WHAT WE'RE DOING TODAY. SO AGAIN THANK YOU ALL FOR COMING HERE, I THINK IT WILL BE IMPORTANT FOR EVERYONE TO KNOW WHO ARE THE MEMBERS OF GROUP THAT WILL BE PARTICIPATING SO AT THIS POINT WE'RE GOING TO GO THROUGH JUST BRIEF INTRODUCTIONS, YOUR NAME, YOUR AFFILIATION AND YOUR INTERESTS. AS A REMINDER, YOU HAVE BEEN MUTED SO PLEASE REMEMBER TO UNMUTE YOURSELF BEFORE YOU BEGIN SPEAKING AND THEN WHEN YOU'RE FINISHED PLEASE MUTE YOURSELF AGAIN SO WE CAN PRESERVE THE AUDYE QUALITY OF THIS MEETING AND THIS RECORDING. SO I WILL BEGIN, MY NAME IS PAIGE CUNNINGHAM. I SERVE AS THE INTERIM PRESIDENT OF TELIA UNIVERSITY. PREVIOUSLY I WAS EXEC TEF DIRECTOR FOR THE CENTER OF BIOETHICS AND HUMAN DIGITY. LAW AND POLICY, MY CURRENT INTERESTS INCLUDE HIGHER ED ADMINISTRATION AND DAILY LIVING AND LEADING WITH COVID-19. SO THAT HAS SEEMED TO BE THE PREDOMINANT INTEREST OF THE LAST 6 MONTHS REGARDLESS OF MY INTENTION TO LAND THERE. WE ARE GOING TO GO THROUGH THIS ALPHABETICAL ORDER SO NEXT WE WILL HEAR FROM GREG BURKE, M. D. DR. BUR KE? >> CAN YOU HEAR ME? >> YES WE CAN. >> THANK YOU, DR. GREG BURKE, I AM A PRACTICING INTERNIST IN HEALTHCARE, PENNSYLVANIA, CHIEF EXPERIENCE OFFICER, HAVE A NUMBER OF ROLES THERE IN ADMINISTRATION BUT MORE IMPORTANTLY HAVE HAD A LONG STANDING INTEREST IN BIOETHICS PARTICULARLY IN THE CATHOLIC TRADITION BUT SECULAR BIOETHICS AS WELL, SERVED AT THE HOSPITAL SYSTEM FOR OVER 25 YEARS AND BEEN INTERESTED IN END OF LIFE ISSUES AND BEGINNING OF LIFE ISSUES AND CONSCIOUS PROTECTION. I HAVE PUBLISHED A NUMBER OF ARTICLES THROUGH NCBC AND OTHER BI ONY ETHICS JOURNALS. CURRENTLY SERVE AS CO CHAIR OF THE CATHOLIC MEDICAL ASSOCIATION'S ETHICS COMMITTEE WHICH IS COMPRISED OF PHYSICIANS, ETHICISTS, THEOLOGIANS, VERY SOLID GROUP AND SPEAK FOR PROBABLY OVER 2000 OF OUR MEMBERS OF THE CATHOLIC MEDICAL ASSOCIATION ON ETHICAL ISSUES. AS I SAID PRACTICING PHYSICIAN HAVE A DEEP, DEEP INTEREST IN THE OUTCOMES OF RESEARCH, HOW THEY'LL AFFECT THE FUTURE OF OUR PATIENTS BUT ALSO THE LEVELS OF COOPERATION THAT THEY REQUIRE WITH ACTION. STATE OF EMERGENCY THAT'S SORT OF A VERY BRIEF INTRODUCTION TO MY WORK. >> THANK YOU DR. BURKE, WE ASKED TO KEEP OUR INTROS BRIEF FOR THE SAKE OF HEARING FROM OUR PUBLIC WITNESSES BEFORE THE PUBLIC PORTION EXPIRES, WE WILL MOVE ON TO MAUREEN CONDUCT, Ph.D. DOCTOR? >> GOOD MORNING, I'M HAPPY TO BE HERE AND SERVE ON THIS COMMITTEE, I'M A PROFESSOR AT THE UNIVERSITY OF UTAH, MY RESEARCH INTERESTS ARE IN THE DEVELOPMENT OF THE NERVOUS SYSTEM. I'VE TAUGHT HUMAN EMBRYOLOGY IN THE MEDICAL SCHOOL FOR OVER 20 YEARS. I ALSO HAVE A GREAT INTEREST IN BIOETHICS AND PUBLISHED EXTENSIVELY AND SPOKEN ON END OF LIFE, BEGINNING OF LIFE, BRAIN DEATH, STEM CELL RESEARCH AND MANY OTHER ETHICAL SCENARIOS. >> THANK YOU. NEXT WE'LL HEAR FROM DR. KEVIN DONOVAN MD-MA. >> HI THERE, KEVIN DONOVAN, I AM A PEDIATRICIAN WITH NEARLY 40 YEARS OF EXPERIENCE. I'VE BEEN IN BIOETHICS AND CLINICAL BY O ETHICS FOR ABOUT 30 YEARS NOW AND ALSO SERVED ON AN IRB FOR 17 YEARS. SO THERE WILL BE NOR PURGATORY FOR ME. I AM CURRENTLY THE DIRECTOR OF THE PELIGRINO CENTER FOR CLINICAL BIOETHICS AT GEORGETOWN UNIVERSITY MEDICAL SCHOOL AND I SPEND ON MOST OF MY TIME EITHER TEACHING, LECTURING, WRITING, PARTICULARLY IN AREAS OF DOCTOR-PATIENTED RELATIONSHIPS, BEGINNING OF LIFE AND END OF LIFE. THANK YOU. >> THANK YOU DR. DONOVAN, NEXT WE WILL HEAR ARE FROM ASHLY FERN NANOG DEZ, MD-Ph.D. >> CA EVERYBODY HEAR ME? >> YES. >> GREAT. I AM ASHLEY FERNANDEZ, I'M AN ACADEMIC PEDIATRICIAN AND PRIMARY CARE AND ASSOCIATE MEDICINE. ASSOCIATE DIRECTOR AT OHIO STATE. MASTERS IN PHILOSOPHY FROM JOHNS HOPKINS AND Ph.D. IN PHILOSOPHY FROM GEORGETOWN UNIVERSITY. I STUDY PHILOSOPHICAL ANTHROPOLOGY, MEDICAL EFFECTS WITH THE HOLOCAUST AND BIOEDUCATION WHERE I'M PUBLISHED AND HAPPY TO BE HERE. >> LET ME JUST PAUSE AND SAY IF I MISS PRONOUNCE YOUR NAME, I APOLOGIZE AND PLEASE CORRECT IT WHEN YOU INTRODUCE YOURSELF. NEXT WE WILL HEAR FROM LAWRENCE GOLD STEIN Ph.D. >> YES, GOOD MORNING. I'M A DISTINGUISHED PROFESSOR AT THE DEPARTMENT OF MEDICINE AND NEUROSCIENCES, I AM ALSO CURRENTLY SCIENTIFIC DIRECTOR OF THE SANFORD CONSORTIUM FOR REGENRATIVE MEDICINE. MY RESEARCH INTEREST FOR THE PAST 10-15 YEARS HAS BEEN IN USING STEM CELLS TO DEVELOP NEW UNDERSTANDING AND NEW TREATMENTS FOR ALZHEIMER'S DISEASE IN RECOGNIZE OF MY SCIENTIFIC CAREER, I'VE WON A NUMBER OF AWARDS AND APOLIPOPROTEIN ALSO AN ELECTED MEMBER OF THE ACADEMY OF ARTS AND SCIENCES AND AN ELECTED MEMBER OF UNITED STATES NATIONAL ACADEMY OF SCIENCES. >> THANK YOU DR. GOLD STEIN, NEXT WE'LL HEAR FROM DR. [INDISCERNIBLE]. >> EYE AM ASHLEY [INDISCERNIBLE], I'M A PRACTICINGNYONATOLOGYST AT THE CHILDREN'S HOSPITAL OF LOS ANGELES IN CALIFORNIA, ASSOCIATED WITH THE UNIVERSITY OF SOUTHERN CALIFORNIA. MY INTEREST IS IN HEALTH SERVICES RESEARCH AND DIGITAL HEALTH AND VERY EXCITED AND HONORED TO BE ON THIS COMMITTEE. >> THANK YOU, DOCTOR. NEXT WE WILL HEAR FROM DR. THOMAS MEDE, MD-Ph.D. >> GREETINGS, DOCTOR AT NORTHWESTERN IN 5 DIFFERENT DEPARTMENTS, I SPEND MOST OF MY TIME WITH BIOSENSORS FOR HUMAN USE AND IMAGING, NONINVASIVE TECHNIQUES FROM ALL SORTS OF IMAGES FROM CANCER TO ALZHEIMERS, YOU NAME IT. THAT'S IT. >> THANK YOU DR. MEDE. NEXT WE WILL HEAR FROM BEN FITCHLE Ph.D. DR. MITCHELL? >> GOOD MORNING. MY INTERESTS ARE MEDICAL ETHICS, BIOTECHNOLOGY, AND PUBLIC POLICY. I DID MY GRADUATE WORK WITH THE UNIVERSITY OF TENNESSEE IN PHILOSOPHY WITH A CONCENTRATION IN MEDICAL ETHICS AND HAVE BEEN INVOLVED IN THAT SINCE THOSE DAYS. HERE AT UNION WE HAVE A SCHOOL OF NURSING AND SCHOOL OF PHARMACY AND SO I HAVE THE PRIVILEGE OF KIND OF ROAMING A BIT AND THAT'S BEEN A GREAT JOY TO ME. AND WITH DR. CUNNINGHAM, I'M DEALING WITH LIFE UNDER COVID-19 TRYING TO CARE FOR AN 87 YEAR-OLD FATHER RIGHT NOW. SO, THANK YOU, IT'S GOOD TO BE HERE TODAY. >> THANK YOU DR. MITCHELL, WE WILL HEAR FROM SUSAN K. MURPHY, PH D DR. MURPHY? >> GOOD MORNING EVERYONE, HAPPY TO BE HERE. ASSOCIATE PROFESSOR AT DUKE UNIVERSITY SCHOOL OF MEDICIE IN THE DEPARTMENT OF OBSTETRICS AND GUIN COALING AND CHIEF OF REPRODUCTIVE SCIENCES. FOR OVER THE LAST 20 YEARS MY PRIMARY RESEARCH INTEREST HAD BEEN FOCUSED ON THE DEVELOPMENTAL ORIGES OF HEALTH AND DISEASE, SO VERY EARLY LIFE AND RECENTLY WE'VE TURNED TO PRECONCEPTUAL ENVIRONMENTS AND HOW THAT HELPS IMPACT THE HEALTH OF DEVELOPING CHILD AND LATER LIFE AND DISEASE. >> THANK YOU NEXT WE WILL HEAR FROM [INDISCERNIBLE]. DR. TED, PLEASE? >> YES, THANK YOU I AM THE DIRECTOR OF EDUCATION FOR THE NATIONAL CATHOLIC BIOETHICS CENTER. AS A GRADUATE STUDENT, I GOT MY DOCTORAL STUDENT RATE IN NEUROSCIENCE WORKING ON EXPRESSION CLONING OF HUMAN NORAEPINEPHRINE TRANSPORTER AND SINCE THAT TIME HAVE HAD A GREAT INTEREST IN THE RELATIONS BETWEEN SCIENCE AND RELIGION AND I HAVE WORKED IN BIOETHICS SINCE ABOUT 2003 FOR THE NATIONAL CATHOLIC BIOETHICS CENTER AND VERY HAPPY TO BE ABLE TO BE PART OF THE DELIBERATIONS TODAY. THANK YOU VERY MUCH. >> THANK YOU, DOCTOR. WE WILL HEAR FROM DR. DAVIS PRENTICE Ph.D. >> THANK YOU DR. CUNNINGHAM. I'M VICE PRESIDENT AND RESEARCH DIRECTOR FOR THE CHARLOTTE OVERINSTITUTE, I HAVE 40 YEARS EXPERIENCE IN TEACHING, MENTORING STUDENTS IN THE AREAS OF CELL BIOLOGY, DEVELOPMENTAL BIOLOGY, EMBRYOLOGY, MOLECULAR BIOLOGY. >> THANK YOU DR. PRENTICE, NEXT WE WILL HEAR FROM KATHLEEN [INDISCERNIBLE] Ph.D., DOCTOR? >> THANK YOU. GOOD MORNING I'M KATHLEEN [INDISCERNIBLE], I AM PROFESSOR OF BIOPHYSICS AND RADIOLOGY AT MEDICAL ONCOLOGY WISCONSIN MY TRAINING WAS IN ENGINEERING AND MEDICINE FROM HARVARD MEDICAL SCHOOL AND MASSACHUSETTS INNSITUTE OF TECHNOLOGY. I HAVE FOCUSED ON RESEARCH IN BRAIN CANCER OVER THE PAST 20 YEARS WHICH HAS INCLUDED A LOT OF WORK WITH IRBs AND TISSUE BANKS. I HAVE ALSO SERVED ON NIH GRANT STUDY SECTIONS FOR OVER 20 YEARS, THANKS. >> THANK YOU DR. [INDISCERNIBLE]. NEXT WE WILL HEAR FROM INGRID SCOTT. >> DR. SCOTT. >> THANK YOU SO MUCH. I AM SO HONORED TO BE PART OF THIS ILLUSTRIOUS GROUP. I AM A CLINICIAN, OBSTETRICIAN GYNECOLOGY IN SAN ANTONIO TEXAS ACCIDENT PRACTICING FOR ABOUT 24 YEARS. I WENT TO MEDICAL SCHOOL AT WASHINGTON UNIVERSITY SO I GOT A VERY GOOD BASIC SCIENCE INSTRUCTION AS A MEDICAL DOCTOR HAVING TO RELEARN A LOT OF THINGS BUT I'M ENJOYING IT. IN MY CLINICAL WORK I'VE BECOME VERY INTERESTED IN ETHICS PARTICULARLY THE ETHICS OF ABORTION AND I'VE PUBLISHED SEVERAL ARTICLES ON THE SAFETY OF ABORTION, MEDICAL ABORTION AND ALSO MATERNAL MORTALITY IN THE RELATIONSHIP TO ABORTION. I'M AN ASSOCIATE SCHOLAR AT THE CHARLOTTE LOSEUR INSTITUTE NTHANK YOU DOCTOR SCOTT, WE WILL HEAR FROM DR. YOST, Ph.D. >> THANK YOU. GOOD MORNING. GLAD TO BE PART OF THIS GROUP, I HAVE--YOU C BERKELEY AND MY INTERESTS ARE IN THE INTERSECTION BETWEEN HUMAN GENETICS AND GERONTOLOGYSTS GOMMICS AND USING MODEL ORGANISMS TO BENEFIT HUMAN HEALTH. I'M THE VICE CHAIR FOR BASIC SCIENCE RESEARCH, WE ABOUT 310 FACULTY AND WE TRIED TO FACILITATE RESEARCH TO IMPROVE THE HEALTH IN CHILDREN. >> THANK YOU VERY MUCH. FOR THOSE INTRODUCTIONS. AND THANK YOU FOR YOUR SERVICE TO THE BOARD. I WILL NOW TURN IT OVER TO MISS CARRY YOUNG WHO'S EXECUTIVE SECRETARY AND DESIGNATED FEDERAL OFFICIAL OF THE ETHICS ADVISORY BOARD FOR DISCUSSION OF CONFIDENTIALITY AND CONFLICT OF INTEREST. >> THANK YOU DR. CUNNINGHAM. FIRST, I WOULD LIKE TO ECHO DR. TABAK IN THANKING ALL OF YOU FOR ALL OF YOUR WORK PREPARING FOR THE MEETING TODAY AND FOR SETTING ASIDE TIME IN YOUR BUSY SCHEDULES TO JOIN US FOR TODAY'S MEETING. WE KNOW THAT SOME OF YOU HAD TO REARRANGE YOUR SCHEDULES AND WE APPRECIATE IT. ON NOTICE OF THE SCHEDULED MEETING WAS PUBLISHED IN THE FEDERAL REGISTER. FOR ACCESSING AND EVALUATING CONTRACT OR GRANT PROPOSALS ALL ETHICS ADVISORY BOARD MEMBER VS READ, AGREEN CELLED TO AND SIGNED THE CONFIDENTIALITY AND NONDISCLOSURE RULES FOR SPECIAL GOVERNMENT EMPLOYEES. MEMBERS SHOULD HAVE ALSO RECEIVED YOUR CONFLICT OF INTEREST FORM AND RECRUCCAL LIST BY NIH SECURE E-MAIL YESTERDAY. IF YOU HAVE NOT ALREADY DONE SO, PLEASE SIGN AND RETURN YOUR FORM TO KIM HATKOWSKI IMMEDIATELY FOLLOWING THE MEETING. ACCORDING TO FEDERAL LAW COUNCIL MEMBERS MAY NOT ENGAGE IN ANY LOBBYING ACTIVITY AS WELL AS SPONSORING FURTHER EVENTS. FURTHER CONFLICT OF INTERESTS ARE IN THE ELECTRONIC BOOK YOU'VE BEEN USING TO REVIEW THE RESEARCH PROPOSALS. THE INFORMATION REGARDING CONFLICTS OF INTEREST IS APPLIED WITH DISCUSSING RESEARCH PROPOSE WILLAS PERINENT TO SPECIFIC ORGANIZATIONS. IF THERE IS A SPECIFIC DISCUSSION ON ANY ORGANIZATION, UNIVERSITY OR TECHNOLOGY WITH WHICH YOU ARE IN CONFLICT, YOU WILL BE BE REQUIRED TO RECRUC YOURSELF FROM THE DISCUSSION AND LEAVE THE VIRTUAL ROOM. THIS WILL BE HANDLED BY OUR VIRTUAL OPERATOR. ONCE THE DISCUSSION OF THE OF THE APPLICATIONS OR PROPOSALS WITH WHICH YOU HAVE A CONFLICT HAVE ENDED. YOU WILL BE REENTERED INTO THE ROOM BY THE OPERATOR. THERE IS NOTHING YOU ARE REQUIRED TO DO ON THE TECHNICAL IF AT ANY TIME A POTENTIAL OR PERCEIVED CONFLICT OF INTEREST ARISES, PLEASE LET ME KNOW IMMEDIATELY AS THE DESIGNATED FEDERAL OFFICIAL. NOW I WILL GIVE A BRIEF DESCRIPTION OF THE PROCEDURES FOR THE CLOSED SESSION OF THE MEETING THAT WILL FOLLOW THIS OPEN SESSION. RESEARCH PROPOSALS WILL BE DISCUSSED 1 THEA A TIME DURING THE CLOSED SESSION OF THE MEETING. EACH PROPOSAL WILL BE CONSIDERED INDIVIDUALLY AND NOT IN COMPARISON TO RPGHT PROPOSALS. MEMBERS OF THIS BOARD WERE ASKED TO REVIEW ALL RESEARCH PROPOSALS WITH WHICH THEY DID NOT HAVE CONFLICTS OF INTEREST PRIOR TO THE MEETING. THE PRIMARY AND SECONDARY REVIEWERS WILL BEGIN DISCUSSION OF EACH PROPOSAL WITH INITIAL COMMENTS AND ASSESSMENTS FOLLOWED BY DISCUSSION BY THE BOARD. VOTING WILL OCCUR AFTER EACH RESEARCH PROPOSAL HAS BEEN DISCUSSED. THE BOARD DOES NOT NEED TO REACH CONSENSUS. THE BOARD SHOULD SEEK TO RAISE AND CONSIDER ISSUES IN A COMPREHENSIVE MANNER SO EACH MEMBER CAN CAST HIS OR HER VOTE AFTER HEARING AND PARTICIPATING IN A THOROUGH DISCUSSION. AS DR. TABAK DESCRIBED, RECOMMENDATIONS FROM THIS BOARD WILL ADDRESS WHETHER THE SECRETARY SHOULD OR SHOULD NOT WITH HOLD FUNDS FROM A PROJECT BECAUSE OF ETHICAL CONSIDERATIONS. NOW I WILL TURN IT BACK OVER TO THE CHAIR OF THIS BOARD DR. CUNNINGHAM FOR THE PUBLIC COMMENT PERIOD. THANK YOU TO THOSE MEMBERS OF THE PUBLIC THAT HAVE JOINED US TODAY. >> THANK YOU MISS YOUNG AND NOW THANK TO YOU THE MEMBERS OF THE PUBLIC WHO SUBMITTED WRITTEN COMMENTS IN ADVANCE OF THIS MEETINGS AND ALSO THOSE OF YOU WHO SIGNED UP TO DELIVER AN ORAL COMMENT DURING TODAY'S OPEN SESSION. FOR THE ETHICS ADVISORY BOARD MEMBERS, THE WRITTEN COMMENTINGS ARE ALSO AVAILABLE REVIEW IN THE ELECTRONIC COUNCIL BOOK SYSTEM YOU'VE BEEN USING TO REVIEW THE RESEARCH PROPOSALS. SO IN ACCORDANCE WITH THE PROCESS OUTLINES IN THE FRN ANNOUNCED IN THIS MEETING, ORAL COMMENTS FROM ALL COMMENTERS WILL BE LIMITED TO 2 MINUTES AND COMMENTERS--EXCUSE ME--COMMENTERS WILL BE MUTED ONCE THERE 2 MINUTES ARE COMPLETE. PLEASE INTRODUCE YOURSELF BEFORE SHARING YOUR THOUGHTS AND WE WILL BEGIN WITH PROFESSOR IRVING WIESSMAN AND I WILL GIVE YOU A MINUTE TO UNMUTE AND WELCOME. >> THANK YOU, I'M HEAD OF THE STEM CELL BIOLOGY AND REGENRATIVE MEDICINE INSTITUTE AT STANFORD UNIVERSITY. THERE ARE FIELDS OF DISCOVERY IN THERAPY THAT ONLY COULD HAVE DEVELOPED WITH HUMAN FETAL TISSUE RESEARCH. HUMAN TISSUES AND ORGANS ARE COMPLEX ARRAYS OF PRECISE ORGANIZED CELLS FROM MANY DIFFERENT PARTS--HERE ARE 2 EXAMPLES FROM OUR OWN 35 YEARS OF RESEARCH IN THIS FIELD. WE TRANSPLANTED THE BLOOD FORMING AND IMMUNE SYSTEMS FROM FETAL REMAINS INTO IMMUNE DEFICIENT MICE. WITH THESE MICE, WE COULD IDENTIFY, ISOLATE AND EVENTUALLY BRING TO HUMAN THERAPIES THE RARE BLOOD FORMING STEM CELLS THAT REGENERATE THE BLOOD FORMING AND IMMUNE SYSTEM. WE SHOWED THAT ISOLATED PURE BLOOD FORMING STEM CELLS RESCUED WOMEN WHO HAVE METASTATIC BREAST CANCER AFTER THEY HAD HIGH DOSE CHEMO THERAPY AND NOW 22 YEARS LATER, WE HAVE FOUND THAT WE CURED 33 PATIENTS, EXTENDED MEDIAN SURVIVAL OF OTHERS FROM 2 TO 10 YEARS. THESE DISCOVERIES HAVE ALSO LED TO AN UNDERSTANDING OF HUMAN LEUKEMIAS WHERE WE WERE ABLE TO DEVELOP AN IMMUNOTHERAPY THAT HAS CURRENTLY BROUGHT NEARLY ALL LEUKEMIA AND MYELODISPLASTIC PATIENTS INTO REMISSION TODAY AND ALSO LYMPHOMA PATIENT WHO IS FAIL ALL OTHER THERP ACTIVITIES AND PROJECTSYS. HUMAN DISEASE VIRUSES CAUSE DISEASE IN THE BODY. WE SHOWED HIV FROM AIDS PATIENTS CAUSED AIDS IN THESE MICE BUT HIV GROWN IN TISSUE CULTURE DID NOT. IT HAD LOST THE ACTIVITY. THIS HAS BEEN A STANDARD TEST FOR NEW DRUGS AND DISCOVERIES FOR OVER 30 YEARS BUT NIH FUNDING WAS STOPPED AS ADMIRAL GIROIR IN 2018, HUMAN FETAL RESEARCH IS THE GOLD STANDARD. EARLY WORK WITH HUMAN FETAL LUNG ADDED TO THESE TISSUES ALLOWED INFECTION WITH SARS VIRUS AND COULD LEAD TO DISCOVERIES AND THERAPIES. I THOUGHT THE FUNCTION OF NIH WAS TO ADVANCE BIOMEDICAL DISCOVERIES TO UNDERSTAND AND TREAT HUMAN DISEASES ESPECIALLY NOW WHEN PATIENTS ONLY HAVE A SHORT WINDOW OF TIME IN WHICH THEY COULD BE TREATED THANK YOU. >> THANK YOU PROFESSOR WEISSMAN, I HAVE BEEN INFORMED WE ARE RUNNING VERY EFFICIENTLY THIS MORNING SO IF YOU WISH TO TAKE LONGER THAN 2 MINUTES HAVE YOU THE FREEDOM TO DO THAT I DON'T WANT TO PUT YOU ON THE SPOT BUT IF THERE ARE ANY OTHER COMMENTS YOU WISH TO MAKE PROFESSOR, YOU COULD DO IT NOW OR AT THE END OF PUBLIC COMMENTS. >> YEAH, I WOULD JUST ADD THAT WE ENTERED THIS FIELD OF RESEARCH BECAUSE BACK IN THE MID1980S PEOPLE WERE DYING OF AN UNTREATABLE EPIDEMIC CALLED HIV. THOSE PEOPLE WHO FELT THAT YOU BED STUDY HIV BY GROWING THE VIRUS IN TISSUE CULTURE, GAVE US A VIRUS, BUT WHEN YOU PUT THAT VIRUS INTO THE HUMAN IMMUNE SYSTEM IN THIS MOUSE OR IN MANY MICE, WE FOUND THAT THE VIRUS HAD LOST ITS ACTIVITY. SO ALL OF THE EFFORTS AND ALL OF THE CLAIMS THAT TISSUE CULTURE WILL GIVE YOU THE SAME ACCURATE RESULT FALLS BY THE WAY SIDE WHEN WUGET TO HUMAN ORGANS. SO I JUST WANTED TO SAY THAT WE COULD FIND A WAY AND IT HAS BEEN UP UNTIL THE ENFORCEMENT OF THE INTRAMURAL BAN, THE METHOD THAT PEOPLE USED TO TEST DRUGS AND THERAPIES. SO I WORRY THAT THESE KINDS OF RESEARCH WHICH FOLLOW ALL THE LEGAL GUIDELINES OF OBTAINING HUMAN FETAL TISSUE IN A NOT FOR PROFIT SETTING FROM WOMEN WHO WERE INFORMED THAT THE FETAL REMAINS COULD BE DO NAILTED BUT AFTER THEY HAD DECIDED OR HAD THE ABORTION, I'M AFRAID THAT THIS WILL CUT OFF A LINE OF EFFORT THAT WE AND OUR FAMILIES AND THE NEXT GENERATION WHEN THEY HAVE THOSE MOMENTS THAT THERE IS A CURE OR NOT A CURE ALREADY THERE, THAT IT HAS NOT ARRIVED. SO THAT'S MY MOTIVATION FOR THIS RESEARCH AND I'M HAPPY TO SAY THAT WE NOW HAVE MANY 10S AT LEAST OF PATIENTS WHO HAVE BEEN TREATED SUCCESSFULLY ONLY BECAUSE OF THIS. >> THANK YOU FOR THOSE EXTEMPORANEOUS COMMENTS PROFESSOR WEISSMAN, NEXT WE WILL HEAR FROM [INDISCERNIBLE]. I WILL GIVE YOU YOU A MOMENT TO UNMUTE YOUR MIKE AND THANK YOU MISS CHAL. >> GOOD MORNING I'M I PROFESSOR OF BI ONITHICS AND UNIVERSITY OF WISCONSIN. I'M HERE TO TELL YOU SOMETHING YOU ALREADY KNOW WHICH IS THAT SCIENCE IS NOT A PARTIS AN ISSUE AND NEITHER IS THE USE OF FETAL TISSUE IN RESEARCH. THE--SO DID THE 1980S FETAL TISSUE TRANSPLANTATION RESEARCH JUDGE WHO HIMSELF WAS A PERSONAL OPPONENT OF ABORTION RIGHTS. WHY? BECAUSE WE ROUTINELY USE TISSUES FROM PEOPLE WHO HAVE DIED, WHETHER CHILD, OR ADULT, OR BABY. AND WHETHER THEY DIED FROM NATURAL CAUSES, ACTS OF NATURE--IN THOSE DEATHS NORWOULD USING THE REMAINS FROM A FETUS MAKE US COMPLICIT IN THE UNDERLYING CAUSE OF ITS DEMISE, NOR DID ANY OF THESE COMMITTEES FIND ANY EVIDENCE THAT THE USE OF THIS TISSUE ENCOURAGES PEOPLE TO HAVE ABORTIONS AND NOTE THAT WAS BEFORE THE CURRENT RULES WERE PUT INTO PLACE TO PREVENT EVEN THAT HYPOTHETICAL POSSIBILITY. IN THE 1990S THE SENATE VOTED 85-12 TO FUND THIS RESEARCH, A THIRD OF THOSE VOTES COMING FROM REPUBLICANS, THE HOUSE PASS THE BILL 260-148 AGAIN BIPARTISAN AND IT'S PRECISELY BECAUSE 1 CAN SUPPORT THE RESEARCH REGARDLESS OF YOUR VIEWS ABOUT APPORTION OR ABORTION RIGHTS THAT SENATOR JOHN McCAIN SPOKE IN FAVOR OF IT REPRESENTATIVE FRED UPTON LOBBIED PRESIDENT GEORGE H. W. BUSH IN FAVOR OF IT AND SENATOR MITCH Mc CONNELL VOTED TO FUND IT. ALMOST EVERY AMERICAN HAS BENEFITED FROM THE USE OF THIS TISSUE AND THE FORM OF ACSEENS WITH POLIO, CHICKEN POX, RUBEILA, AND OTHERS, SCIENTISTS PROPOSE USING IT WHEN IT HAS DISTINCT MEDICAL VALUE. THROWING UP BARRIERS WILL ONLY LIMIT OUR HOPE FOR CURING AND PREVENTING DEVASTATING DISEASES AND MAKE INNOCENT PATIENTS THE COLLATERAL DAMAGE OF WORK. >> THANK YOU, IF YOU WISH TO MAKE MORE COMMENTS YOU'RE WELCOME TO DO SO. >> OH THAT'S VERY KIND OF YOU. I REMEMBER WELL SITTING NEXT TO YOU AT THE PANEL AND I APPRECIATED HOW CIVILLET DISCOURSE WAS THERE, THANK YOU. ONE THING I DIDN'T HAVE TIME TO SAY THAT I WOULD LIKE TO OFFER UP. ANOTHER OBJECTION I HEARD IS THAT A WOMAN WHOSE CHOSEN TO HAVE AN ABORTION HAS NOW LOST THE MORAL AUTHORITY TO BE THE PERSON WHO GIVES CONSENT TO HAVE THE REMAINS USED FOR RESEARCH PURPOSES. AND WHILE I APPRECIATE THE NATURE OF THAT CONCERN I DID WANT TO POINT OUT THAT IT IS NOT UNKNOWN FOR US TO DO THINGS LIKE THIS. IN MANY STATES IN THE U.S., CORNEAS ARE TAKING FROM THE BODIES OF PEOPLE WHO HAVE BEEN WOUND UP IN THE CORONER'S OFFICE, USUALLY CRIME VICTIMS, THEY'RE TAKEN WITHOUT CONSENT IS THE REASON IS THAT THE NEED FOR THE TREATMENT OF BLINDNESS HAD TRUMPED ANY CONCERN ABOUT THE NEEDS OF THE DEAD SINCE THEY COULD NO LONGER EXPERIENCE THE LOSS OF THE CORNEAS, AND RECOGNIZING THAT EVEN WITH OPEN COFFINS AND OPEN CASKET WAKES THIS WOULD NOT BE SOMETHING VISIBLE TO THE FAMILY SO WE HAVE AWNCH HAD THESE DIFFICULT BALANCING ACTS AND HAVE CHOSEN TO FAVOR THE NEEDS OF THE PEOPLE WHO ARE CURRENTLY LIVING. >> THANK YOU MISS CHARLOTTE, IT IS GOOD TO SEE YOU AGAIN. NEXT WE WILL HEAR FROM THOMAS MARRIANA Ph.D. I WILL GIVE YOU A MOMENT TO UNMUTE YOUR MICROPHONE. DOCTOR? >> THANK YOU. I HOPE YOU CAN HEAR ME I'M TOM MARRIANY, I AM VICE PRESIDENT CHAIR FOR RESEARCH IN THE DEPARTMENT OF PEDIATRICS AT THE CHILDREN'S HOSPITAL AT THE UNIVERSITY OF ROUGH ATOM CHESTER IN THE GREAT STATE OF NEW YORK. I'M HERE REPRESENTING THE AMERICAN THORACIC SOCIETY TODAY WHICH IS A DIVERSE GROUP OF OVER 16,000 CLINICIANS AND SCIENTISTS THAT ARE DEDICATED TO THE PREVENTION, TREATMENT AND CURE OF PULL MONITORARY CRITICAL CARE AND SLEEP RELATED ILLNESSES. WE AS A GROUP RECOGNIZE THE MANY PAST CONTRIBUTIONS TO SCIENCE AND MEDICINE MADE POSSIBLE BY INCORPORATING THE USE OF HUMAN FETAL TISSUES INTO RATIONAL AND ETHICAL RESEARCH PROJECTS. FOR 1 EXAMPLE, STUDIES WITH HUMAN FETAL TISSUES WERE ABSOLUTELY ESSENTIAL TO DESIGN THE MECHANISMS FOR THE PRODUCTION OF PULL MONITORARY SURFACTANT LEADING TO NEW INTERVENTIONAL STRATEGIES TO COMBAT THE NEW LEADING CAUSE OF DEATHS IN INFANTS, AN AFFLICTION THAT TOOK THE LIFE OF A CHILD OF A SITTING PRESIDENT OF THE UNITED STATES, JOHN F. KENNEDY. THERE ARE A NUMBER OF BENEFITS OF USING HUMAN FETAL TISSUE, NOT THE LEAST OF WHICH IS THAT CELL LINES DEVIEF FRIDAY HUMAN FETAL TISSUES HAVE WIDELY BEEN USED AND CONTINUE TO BE USED AS A MAJOR SOURCE, RESOURCE FOR THE DEVELOPMENT OF VACCINES INCLUDING THOSE SIMILAR TO SARS-COV-2. IT IS IMPORTANT AGAIN TO NOTE THAT NO ALTERNATIVES CAN REPLACE THE USE OF HUMAN FETAL TISSUES FOR MANY CONTEMPORARY RESEARCHA APPLICATIONS AS DR. WEISSMAN MENTIONED. ONE EXAMPLE, A 2018 NIH WORKSHOP CONCLUDE THAD HUMAN FETAL TISSUE DERIVED HUMANIZED IMMUNE SYSTEM MODELS SUCH AS THE 1 DR. WEISSMAN MENINGED REMAINS THE GOLD STANDARD TO WHICH OTHER MODELS SHOULD BE COMPARED. FINALLY, WE WOULD LIKE TO EMPHASIZE THAT THOROUGH ETHICAL REVIEW FOR ALL RESEARCH PROJECTS USING HUMAN SUBJECTS AND HUMAN FETAL TISSUES ARE CONDUCTED AT THE LOCAL AND REGIONAL LEVEL BY INSTITUTIONAL REVAW BOARDS FOLLOWING NATIONAL GUIDELINES. THESE BOARDS HAVE SUCCESSFULLY SERVED FOR DECADES TO INSURE THAT RESEARCH IS COMPLIANT WITH ETHICAL STANDARDS IN REGULATIONS AND HAVE THE AUTHORITY TO APPROVE, DISAPPROVE, MODIFY AND AND/OR MONITOR RESEARCH PROJECTS. IN CONCLUSION--HUMAN FETAL TISSUES AND RESEARCH STUDIES THAT ARE JUDGED TO BE SCIENTIFICALLY MERITORIOUS. ETHICAL CONSIDERATIONS SHOULD CONTINUE TO BE EVALUATED AT THE LOCAL AND REGIONAL LEVEL USING THE INSTITUTIONAL REVIEW BOARD PROCESS. THE ON BEHALF OF THE ATS, I THANK THE BOARD FOR THIS OPPORTUNITY TO MAKE THESE COMMENTS. >> THANK YOU DR. MARRIANY, IF YOU WAISH TO MAKE ANY ADDITIONAL COMMENTS FEEL FREE TO DO SO. >> NO THANK YOU, I APPRECIATE THE OFFER FOR THE TIME. >> ALL RIGHT, THANK YOU FOR YOUR CONTRIBUTION. NEXT WE WILL BE HEARING FROM MARIA PHENNEY, Ph.D., I WILL GIVE YOU A MEMORY CLONE TONIGHT UNMUTE. DR. PHENNEY? >> MISS YOUNG IS THE DOCTOR PARTICIPATING IN THIS MEETING, I CANNOT FIND HER. >> I DON'T SEE HER IN THE MEETING SO PERHAPS WE CAN MOVE ON TO THE NEXT PERSON IF GET HER BACK IF SHE DOES JOIN. >> ALL RIGHT, WE WILL DO SO. NEXT WE WILL HEAR FROM JAMES œYOU A MEMORY CLONE TONIGHTVE UNMUTE YOUR MICROPHONE. DR. SHIRLEY? >> THANK YOU. I'M JAMES SHIRLEY, DIRECTOR OF THE BIOTECHNOLOGY STEM CELL COMPANY ASYMMETRICS. MEMBERS OF THE COMMITTEE, HAVE YOU BEEN CALLED UPON TO REVIEW AND JUDGE THE ETHICAL CONDUCT OF RESEARCH AND DEVELOPMENT ACTIVITIES WHOSE POTENTIAL BENEFITS ARE SELF-EVIDENT. THERE ARE FEW WHO ARGUE AGAINST THE POSITION THAT GENERALLY BIOMEDICAL RESEARCH AND FORM SUITICAL DEVELOPMENT ARE GOOD AND ESSENTIAL FOR THE NATION. IN THE LONG-TERM AND IN THE SHORT-TERM. AND EVEN THOUGH OFTEN RESEARCH SUBJECTS MAY NOT BENEFIT DIRECTLY, THEY RECEIVE THE GRATITUDE AND ACKNOWLEDGMENT FOR THEIR ALTRUISM. THE ETHICAL CONSIDERATIONS FOR THE CONDUCT OF MOST RESEARCH ARE STRAIGHT FORWARD WITH LITTLE CONTROVERSY. INFORMED CONSENT IS REQUIRED, SAFETY IS PREEMINENT, AND NO UNDUE INJURY OR DEATH, RESEARCH SUBJECT SYSTEM ACCEPTABLE. THE CHALLENGE YOU NOW HAVE IS HOW TO THINK ABOUT THE SAME ETHICS PRINCIPLES FOR RESEARCH ACTIVITIES IN WHICH THE EFFECTIVE RESEARCH SUBJECT IS ACTIVELY DISPLACED FROM THE RESEARCH EEIVET. ALWAYS IN SPACE AND OFTEN IN TIME, IN THE CASE OF RESEARCH THAT UTILIZES TISSUES AND CELLS PROCURED FROM ELECTIVELY,A BORTED FETUSES, THE RESEARCH COMMUNITY HAS AN OBVIOUS ANSWER. THERE IS NONE. BUT GIVEN THAT THE FETUS' DEATH IS NECESSARY, IS A NECESSARY EVENT FOR THE RESEARCH, IT IS YOUR ETHICAL RESPONSIBILITY TO MAKE SURE THAT THAT RESEARCH DOES NOT CAUSE THE DEATH. THERE ARE ALSO STRONG ETHICAL ARGUMENTS AGAINST SUCH RESEARCH EVEN IF IT DOES NOT MOTIVATE FETAL-- >> DR. SHIRLEY, I BELIEVE YOUR VIDEO HAS FROZEN. COULD WE HAVE SOME TECHNICAL ASSISTANCE PLEASE. >> LOOKS LIKE DR. PHEIN, NEY, SO MAYBE WHILE WE TRY AND SORT THAT OUT WE CAN HAVE DR. PHENNEY, GIVE HER REMARKS. >> SO DR. SHIRLEY, I APOLOGIZE FOR THE TECHNICAL GLITCH, WE WILL ALLOW YOU TO RETURN AND GIVE YOUR FULL TESTIMONY, AT THIS POINT, MARIE, I WILL GIVE YOU A MINUTE TO UNMUTE YOUR MICROPHONE AND REMIND YOUA THE END OF YOUR COMMENTS TO PLEASE MUTE AGAIN. DR. PHEIN, NEY. >> I THANK YOU, I APOLOGIZE MY TIME SLOT CHANGED, I WAS WATCHING BUT NOT ON. THANK YOU FOR THE OPPORTUNITY. I'M A SCIENTIFIC CONSULTANT--[ECHO ]--DO YOU HAVE YOUR WEBCAST ON? >> SO WE'RE ALL GETTING-- >> DR. LET'S JUST TAKE A MOMENT WOULD YOU PLEASE BEGIN FROM THE TOP. ABSOLTELY, THANK YOU SO MUCH APPROXIMATE MUCH FOR THIS OPPORTUNITY. I'M A SCIENTIFIC CONSULTANT SPECIALIZING IN PHARMACEUTICS BIOCHEMISTRY AND BIOTECHNOLOGY. I BECAME A SCIENTIST TO SERVE HUMANITY AND THIS REQUIRES US TO WORK IN A WAY THAT RESERVES AND PROPOTENT STATES--PRESERVE AND PROMOTES OF EACH AND EVERY AGE, DEVELOPMENTAL, LEVEL OF DEPENDENCE, WHY SHOULD BE WE CONCERNED ABOUT FUNDING RESEARCH USING ABORTION DERIVED FETAL TISSUE? ONE, HISTORY IS REPEATING ITSELF AS WE EXPLOIT 1 GROUP OF HUMAN BEINGS FOR THE BENEFIT OF ANOTHER GROUP. IN CASES OF INCLUESED ABORTION, IT IS IMPOSSIBLE TO OBTAIN VALID INFORMED CONSENT FROM THE FETUS OR FROM A GUARDIAN ACTING IN THE BEST INTEREST OF THE FETUS. TWO, I AM CONCERNED FOR THE MOTHER. --DONATION BY THOSE HO HAVE A PROFESSIONAL AND SOMETIMES A FINANCIAL INTEREST IN OBTAINING HER CONSENT. THREE, CERTAIN ABORTION DERIVED MATERIALS HAVE BECOME SO WIDESPREAD THROUGHOUT BIOMEDICAL RESEARCH THAT IT'S DIFFICULT TO AVOID THEM FOR RESEARCHERS LIKE ME AND PATIENT WHO HAVE CONSCIENCE OBJECTIONS. FOUR, A MARKET EXISTS IF ARE ABORTION DERIVED MATERIALS WHICH CREATES INCENTIVES FINANCIAL AND OTHERWISE FOR GREATER COOPERATION BETWEEN TISSUE PROCUREMENT ORGANIZATIONS AND ABORTION PROVIDERS. THIS ADVISORY BOARD CAN CHOOSE TO BE AT THE FOREFRONT OF PROMOTING NONCONTROVERSIAL TISSUE AND CELL SOURCES. SCIENCE IS ONLY SCRATCHED THE SURFACE OF WHAT IS POSSIBLE WITH INN DUCED PLURIPOTENT STEM CELLS, ORGANOIDS, PERINATAL CELLS FROM UMBILICAL CORD, PLACENTA AND AMNIOTIC FLUID AND NAMING JUST A FEW, IMAGINE WHAT IS POSSIBLE IF WE COMMIT TO MOVING FORWARD ON THIS COMMON GROUND. THANK YOU VERY MUCH. >> THANK YOU DR. FEENEY, WE ARE ALLOWING ALL OF OUR PUBLIC COMMENTERS TO MAKE EXTEMPORANEOUS COMMENTS IF YOU WISH TO DO SO. >> I THINK I SAID EVERYTHING I WOULD LIKE TO SAY, THANK YOU SO MUCH. >> THANK YOU DR. FEENEY, AT THIS POINT WE WILL MOVE TO DR. SHIRLEY, FOR THE SAKE OF RECORDING AND BECAUSE WE HAVE TIME WOULD YOU PLEASE BEGIN FROM THE TOP DR. SHIRLEY. >> THANK YOU, I WILL DO THAT PRESENTLY. MEMBERS, HAVE YOU BEEN CALLED UPON TO REVIEW THE ETHICAL CONDUCT AND RESEARCH ACTIVITIES WHOSE POTENTIAL BENEFITS ARE EVIDENT. THERE ARE FEW WHO ARGUE THAT GENERALLY BIOMALRESEARCH AND PHARMACEUTICAL DEVELOPMENT ARE GOOD FOR THE NATION IN THE SHORT THERMOGENESIS AND THE LONG-TERM AND EACH THOUGH OFTEN RESEARCH SUBJECTS MAY NOT OFTEN BENEFIT DIRECTLY, THEY RECEIVE THE GRATITUDE AND ACKNOWLEDGMENT FOR THEIR ALTRUISM. THE ETHICAL CONSIDERATIONS FOR CONDUCT OF MOST RESEARCH ARE STRAIGHT FORWARD WITH LITTLE CONTROVERSY, INFORMED CONSENT IS REQUIRED, SAFETY IS PREEMINENT AND NO UNDUE INJURY OR DEATH TO RESEARCH SUBJECT SYSTEM ACCEPTABLE. THE CHALLENGE YOU NOW HAVE IS HOW TO THINK ABOUT THE SAME ETHICS PRINCIPLES FOR RESEARCH ACTIVITIES IN WHICH THE AFFECTED RESEARCH SUBJECT IS DISPLACED FROM THE RESEARCH EVENT. ALWAYS IN SPACE AND OFTEN IN TIME. IN THE CASE OF RESEARCH THAT UTILIZED CELLS FROM ELECTIVELY ABORTED FETUSES, THE RESEARCH SUBJECTS HAS AN OBVIOUS ANSWER, THERE IS NONE BUT GIVEN THAT THE FETUS' DEATH IS A NECESSARY EVENT FOR THE RESEARCH, IT IS YOUR ETHICAL RESPONSIBILITY TO MAKE SURE THAT THE RESEARCH DOES NOT CAUSE THE DEATH. THERE ARE ALSO STRONG ETHICAL ARGUMENTS AGAINST SUCH RESEARCH EVEN IF IT DOES NOT MOTIVATE FETAL DEATHS BUT IF IT DOES THESE ARGUMENTS GROW EVEN STRONGER. IF RESEARCH FOR HUMAN FETAL TISSUE IS IN ANY WAY EVEN A SMALL PART CONTRIBUTORY TO MOTIVATING ELECTIVE ABORTIONS THEN THE ETHICAL ASSESSMENT IS STRAIGHT FORWARD. SUCH RESEARCH WOULD CONSITUTE ETHICAL MISCONDUCT THAT SHOULD NOT BE FUNDED BY THE U.S. GOVERNMENT OR ALLOW BY PRIVATE AGENCY EITHER. THE RESEARCH OF MY COLLEAGUES AND I PROVIDE SUBSTANTIAL EVIDENCE THAT SUCH ETHICAL MISCONDUCT OCCURS FREQUENTLY, WE RECALL THAT WORK OF OTHERS AS YOU ARE INFORMED FOR THE DELIBERATIVE PROCESS. THANK YOU. >> THANK YOU DR. SHIRLEY IF YOU WAISH TO MAKE ANY EXTEMPORANEOUS COMMENTS, YOU ARE FREE TO DO SO NOW. >> I WOULD ONLY MAKE 1 COMMENT REGARDING THE PROCESS, I THINK, I WOULD SUGGEST TO THE BOARD GOING FORWARD THAT THERE IS AN EARLIER DEADLINE FOR PUBLIC COMMENT AND THAT WAY, THE BOARD WILL HAVE TIME TO LACK AT THOSE COMMENTS AS THEY THEMSELVES ARE REVIEWING PROPOSALS AND NOT IN THE MOMENT OF THE JOINT REVIEW. THANK YOU. >> THANK YOU DR. SHIRLEY. THIS CONCLUDES THE PORTION OF THE ORKSZ FICIAL PUBLIC COMMENTERS, WE WANT TO MAKE SURE AND I WANT PAUSE AND MAKE SURE I HAVE NOT MISSED ANYONE WHO WILL MAKE A PUBLIC COMMENT. MISS YOUNG, CAN YOU CLARIFY? >> YES WE HAVE GONE THROUGH EVERYONE WHO SIGNED UP TO GIVE A PUBLIC COMMENT, SO I THINK WE'RE GOOD. >> SO IF I MAY TAKE THE PREROGATIVE OF THE CHAIR KNOWING THE DAY WE HAVE AHEAD, I PROPOSE WE CONCLUDE THE PUBLIC PORTION OF THE MEETING AND MOVE INTO THE CONFIDENTIAL SESSION.